Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Agouron Pharmaceuticals (AGPH) -- Ignore unavailable to you. Want to Upgrade?

To: WAH who wrote (3088)	12/3/1997 10:09:00 AM
From: Oliver & Co	Respond to of 6136

You should also follow the percentage of your T Cells. The absolute number of T Cells depends on you total Lymph count. I have found many cases where you see a decline in the # of T Cells, but the % is either the same or many times higher. So that a drop may actually not mean very much. Most patients who are doing well will have continuous increases on the percent of their CD4 cell, towards normalization. Regarding this guy, David Crosson, I first heard of him around Oct 1st, when he downgraded AGPH based on an obscure study. He now comes back with all these anal-ysis, and predicting that multiple PIs(from ABBOTT, from Glaxo and another from Vertex) will be coming in the market next year. This info is at best erroneous, at worst misleading and a lie to drop the value of the stock. I do not know why he is doing this, but I am sure it is not benign. Good luck to you. JLL